BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
BioJournal - Datamonitor

http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor.html

Stakeholder Opinions Head and Neck Cancer
Stakeholder Opinions Head and Neck Cancer
Key issues in head and neck cancer including disease overview and epidemiology, current treatment patterns and controversies, unmet needs and key stakeholder opinions. The clinical pipeline and profiles of the late-phase products are also included.
Commercial and Pipeline Insight - Systemic antifungals
Commercial and Pipeline Insight - Systemic antifungals
The systemic antifungals market accounts for $3.1bn of the total $41bn anti-infectives market. A wave of new products coinciding with patent expiry of two widely used compounds will shake up the market for systemic infections, further polarizing between winners and losers. Key changes are forcing a rethink of management strategies and clinical trial design.
Pipeline Insight - Orphan Diseases in CNS - Part I Huntington's Disease
Pipeline Insight - Orphan Diseases in CNS - Part I Huntington's Disease
The current Huntington’s disease market is comprised of off-label prescriptions of psychotropic drugs. In the near term, two pipeline drugs are set to enter the market, demonstrating the viability of this disease as a primary marketing indication. In the longer term, with a strong genetic link and reliable diagnostic test, prophylactic treatment with a disease modifying drug could prove lucrative.
Licensing Strategies - Examining Today’s Pharmaceutical Licensing Trends
Licensing Strategies - Examining Today’s Pharmaceutical Licensing Trends
With Pharma struggling to maintain its pipelines and portfolios with products developed in-house, companies are increasingly turning to licensing. However, the search for late-stage developmental products is becoming tougher and more expensive, and companies are now looking towards licensing earlier-stage compounds.
Pipeline Insight - Substance Dependence - Part I - Nicotine
Pipeline Insight - Substance Dependence - Part I - Nicotine
The high prevalence of nicotine dependence, strong uptake of Pfizer’s Chantix (varenicline), and the launch of new innovative therapies will cause the nicotine dependence prescription drug market to grow to $4.6 billion across the seven major markets by 2016. Innovative therapies are set to offer patients a convenient dosing regimen and thereby carrying the potential for improved compliance.
Commercial and Pipeline Insight - Hepatitis B
Commercial and Pipeline Insight - Hepatitis B
Fuelled by an increasing disease awareness, the growing use of new, expensive drugs as well as combination therapy, the HBV drugs market, sized at $431m in 2006 across the seven major markets, will nearly triple in size by 2016. Rapid growth until 2011 will slow down in the following years as a result of genericization and the beginning impact of routine HBV vaccination.
Cardiovascular market overview - Raft of patent expires threaten blockbusters
Cardiovascular market overview - Raft of patent expires threaten blockbusters
Datamonitor expects the cardiovascular market to remain stable with sales only showing negligible growth between 2006 and 2016, below the 3% growth predicted for the SU sold. Generic products will become increasingly important as the majority of products will have lost IP protection, accounting for 30% of cardiovascular sales and 65% of SU sold in 2016.
Molecular Targeted Cancer Therapies  Can anything else revolutionize the market
Molecular Targeted Cancer Therapies Can anything else revolutionize the market
Approaches to cancer treatment continue to incorporate molecular targeted therapies into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge.
Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family
Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family
Drug targets are the critical link between drugs and their role in the treatment of medical disorders. By grouping drug targets into key protein families, this report provides a comprehensive analysis of the prescription pharmaceutical market by not just molecule type and therapy area, but also by target family.
Acute Stroke - TPA spurs infrastructure changes for the better
Acute Stroke - TPA spurs infrastructure changes for the better
Stroke is one of the top three leading causes of death worldwide and an area of high unmet needs. TPA is limited to a low number of ischemic stroke patients due to a short therapeutic time window, but it is still the best therapy available. TPA is responsible for major changes and advances in the way stroke patients are cared for, which is expected to evolve further.
Renal Cancer - Targeted therapies rapidly take hold of market
Renal Cancer - Targeted therapies rapidly take hold of market
In the 7 major markets, Datamonitor estimates that the incidence of RCC in 2007 will total 86,800 cases. Around 25% of all RCC patients are diagnosed with Stage IV disease; the 2-year survival rate for these patients is around 23%. This low survival rate and the fact that a significant proportion of Stage IIII patients relapse with Stage IV disease mean there is significant unmet need in RCC.
Antithrombotics - Market expands as disease management focuses on prevention
Antithrombotics - Market expands as disease management focuses on prevention
Datamonitor expects the antithrombotics market to peak at just over $20 billion in 2012, across the seven major markets. The growth will be driven by the uptake of the novel oral anticoagulants - Bayer's Xarelto and BI's Rendix - which are expected to launch simultaneously, in 2008.
Infertility - Optimizing a market bounded by social opinion and physician preference
Infertility - Optimizing a market bounded by social opinion and physician preference
The market for infertility drugs is a complex and dynamic arena shaped by numerous factors such as changing social attitudes, national legislation, and prescriber preferences. Brand strength and diverse portfolios have allowed Organon, Merck Serono and Ferring to secure a firm foothold in the market, worth over $1 billion in 2006, and represent tough competition.
Commercial and Pipeline Insight Allergic Rhinitis
Commercial and Pipeline Insight Allergic Rhinitis
The allergic rhinitis market will continue to decline over the next few years, after which it will resume limited growth due to the introduction of new compounds and combination products. These will drive the expansion of sales in existing classes as they exhibit safety and convenience advantages. Meanwhile, immunotherapy is expected to move from its niche position into mainstream therapy.
Upper GI Disorders - Innovation needed to overcome generic threat
Upper GI Disorders - Innovation needed to overcome generic threat
The upper GI market, defined as gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD) and dyspepsia indications, achieved sales of just over $19 billion in 2006, with minimal growth since 2005. All major PPI brands will lose patent protection in the next 10 years, resulting in a major increase in generics and a declining market value.
HIV Therapy Dynamics
HIV Therapy Dynamics
Despite several developments in efforts to tackle the spread of HIV, the total number of people living with HIV has continued to increase across the 6MM. However, significant advances in HIV disease understanding, treatment and management mean that the outlook for patients has considerably improved.
Orthopedics: Global Industry Guide
Orthopedics: Global Industry Guide
Datamonitor's Orthopedics: Global Industry Guide is an essential resource for top-level data and analysis covering the orthopedics industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Biotechnology: Global Industry Guide
Biotechnology: Global Industry Guide
Datamonitor's Biotechnology: Global Industry Guide is an essential resource for top-level data and analysis covering the biotechnology industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis
Generics: Global Industry Guide
Generics: Global Industry Guide
Datamonitor's Generics: Global Industry Guide is an essential resource for top-level data and analysis covering the generics industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Biosimilars Series Strategic issues - Potential remains uncertain
Biosimilars Series Strategic issues - Potential remains uncertain
Significant barriers to entry into the biosimilars market exist. High up-front investment and the need for specific expertise favor big players. Understanding of the marketplace is critical for success acceptance by key stakeholders is crucial for market uptake of biosimilars and achieving preferential reimbursement status through constant review of the pricing strategy is desirable.

 

Cancer Overview - Increasing diversity offers both high risk and reward
Cancer Overview - Increasing diversity offers both high risk and reward
In 2007, more than 3 million new cases of solid tumors are forecast to be diagnosed across the seven major pharmaceutical markets, obviously representing an enormous market potential. Lower incidence tumor types are becoming increasingly attractive to drug developers, due to high levels of unmet need which can result in significant financial rewards.
Parkinson's Disease - Market to grow as first round of lifecycle management strategies succeed
Parkinson's Disease - Market to grow as first round of lifecycle management strategies succeed
The PD market is set to continue to grow over the next 7 years, reaching over $2.37 billion in 2013, a 39% increase from 2006 levels. Combinations, reformulations, and indication expansions will drive the majority of this growth, with key brands expected to be Novartis/Orion's Stalevo, GlaxoSmithKline's (GSK's) Requip Modutab, and UCB-Schwarz's Neupro.
Pricing and Reimbursement Series NICE  its impact on the UK healthcare system and beyond
Pricing and Reimbursement Series NICE its impact on the UK healthcare system and beyond
NICE is one of the most advanced cost effectiveness assessment bodies operating in the major pharmaceutical markets. Since it was established it has had an increasing impact on the availability of new drugs in England and Wales, but has also generated considerable attention globally
Neuropathic Pain - Emerging drugs fail to capitalize in lucrative market
Neuropathic Pain - Emerging drugs fail to capitalize in lucrative market
The neuropathic pain market is forecast to double from 2006 to reach over $7 billion by 2016. At this time, the current late-stage neuropathic pain pipeline is forecast to take only 18% of the total market share, highlighting an opportunity for better pipeline drugs that demonstrate improved pain management. The most promising and closest pipeline drug to market is UCB's Vimpat (lacosamide).
Migraine - Opportunities will exist in the wake of generic attack
Migraine - Opportunities will exist in the wake of generic attack
With the seven triptan brands continuing to dominate acute migraine treatment and Ortho-McNeil's Topamax (topiramate) driving sales in the prophylactic market, 7MM revenues of anti-migraine drugs increased by 8.1% from 2005 to $3.7 billion in 2006. The US accounted for 80% of the 7MM total in 2006, Whilst in the 5EU, France is the largest market for migraine-specific drug sales.
Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff
Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff
"IntroductionThis report provides a comprehensive strategic analysis of the mAb market out to 2012 by company. It identifies four 'established' and four 'emerging' players within the mAb sector which are forecast to play the most commercially significant role within this market.
Osteoporosis Intermittent dosing drives market growth
Osteoporosis Intermittent dosing drives market growth
The long-standing unmet need of the osteoporosis market has been for improved adherence to treatment. Two pipeline products, Amgen's Denosumab and Novartis' Aclasta (zoledronate), have answered this demand with intermittent dosing schedules and consequently are expected to generate blockbuster revenues. This will rejuvenate the market which is otherwise stalling under multiple patent expiries.
Biosimilars Series Regulatory and development issues hurdles exist but are surmountable
Biosimilars Series Regulatory and development issues hurdles exist but are surmountable
Europe serves as a model for other countries looking to define their own regulatory approval criteria. The US is on the brink of passing legislation to establish a statutory pathway for biosimilars approval but the opposing interests of biosimilar and innovative companies may result in further delays. Development of biosimilars presents many challenges and potential pitfalls.
Hospital Antibacterials A market beyond MRSA
Hospital Antibacterials A market beyond MRSA
The Hospital antibacterials market accounted for $9.9bn of the total $41bn anti-infectives market. Increasingly resistant and problematic pathogens make this an attractive target for premium priced products outside of the largely genericized Community market. However, high concentrations of patent expiries and similarly targeted product launches imply a highly competitive commercial landscape.
Business Blogging for Pharma
Business Blogging for Pharma
Social media are shifting the way that the global economy operates. Internet journals and communities have enabled consumers to communicate their experiences with companies' products and services to other consumers. A consequence of consumer-generated marketing is that relationship management throughout the lifecycle of a product is taking the place of mass marketing in consumer-driven industries.
Antidiabetics Safety becomes the critical factor for success
Antidiabetics Safety becomes the critical factor for success
The diabetes epidemic has contributed in the growth of the antidiabetics market the past few years. Since the prevalence of diabetes continues to increase, the market will further expand. While early therapy is dominated by generically available agents, and the later stages by insulin, the number of unmet needs in the diabetes treatment, warrants that novel agents will have a place in the market.
Launch Strategies Analyzing Market Trends and Regulatory Impacts
Launch Strategies Analyzing Market Trends and Regulatory Impacts
With fewer truly novel products entering the market, combined with increasing developmental time and spend, and declining ROI, successful launches have never been more important for pharmaceutical companies. Therefore, to ensure a successful launch, manufacturers must employ a multitude of timely strategies to ensure their product enter the market as soon and as smoothly as possible.
Heart failure Weak pipeline dominated by new indications and add-on diuretics
Heart failure Weak pipeline dominated by new indications and add-on diuretics
Datamonitor expects few new products to emerge from a week pipeline for both acute and chronic heart failure. Sales in the seven major markets will be modest with all the new drugs being add-on therapies to current standard regimes. Significant unmet patients needs will remain in both acute and chronic heart failure.
R&D Strategies Incremental improvements and paradigm shifts in strategy are both necessary to boost productivity
R&D Strategies Incremental improvements and paradigm shifts in strategy are both necessary to boost productivity
Waves of technological advancements have powered significant evolution in R&D from serendipitous drug discovery, through to rational drug design. However, as the low-hanging fruit has been picked, and recent technological advances have failed to yield high numbers of new therapies, the search is on to identify R&D strategies to improve R&D productivity
Female Sexual Dysfunction Prescription Drug Pipeline Overview 2007
Female Sexual Dysfunction Prescription Drug Pipeline Overview 2007
Female sexual dysfunction (FSD) affects an estimate 84 million women across the seven major pharmaceutical markets and represents a significant opportunity for investment. Despite its high prevalence, FSD is poorly understood and defined. Currently there is just one product approved for the treatment of FSD; P&G's Intrinsa (testosterone) is marketed in Germany, France and the UK.
Pediatric and Adolescent Vaccines
Pediatric and Adolescent Vaccines
The pediatric and adolescent vaccines market encompasses many different classes. DTP and MMR combinations continue to form the mainstay of childhood immunization; however, their growth potential is limited. The key opportunities lie in novel, innovative additions to established schedules, particularly pneumococcal (Prevnar), conjugated meningococcal (Menactra) and HPV (Gardasil) vaccines.
Patient Empowerment empowered patients can change healthcare outcomes and impact the pharmaceutical industry
Patient Empowerment empowered patients can change healthcare outcomes and impact the pharmaceutical industry
Datamonitor has identified the key trends and events that drive patient empowerment and impact the pharmaceutical industry. These range from the increased access to information via internet and the rising pressures of cost containment through to how patient empowerment is affecting access to drugs as well as changing pharmaceutical marketing strategies and their public image.
Antihypertensives New class opportunity offset by key patent expiries
Antihypertensives New class opportunity offset by key patent expiries
Datamonitor expects the antihypertensives market to reach almost $40 billion, across the seven major markets, by 2016. The growth will be driven by the uptake of Novartis's Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizer's Norvasc and Merck's Cozaar, will restrain market growth.
Antidyslipidemics The competitive cost-conscious antidyslipidemics market presents challenges
Antidyslipidemics The competitive cost-conscious antidyslipidemics market presents challenges
The restrictive, highly competitive antidyslipidemic market is going to become even further genericized, which will add to the challenges that drug makers are facing. Despite over 300m people being eligible for antidyslipidemic treatment, there is still a lot of under-diagnosis and under-treatment, but it will be a major issue capturing all the eligible population.
Asthma and COPD Combination products still have blockbuster potential
Asthma and COPD Combination products still have blockbuster potential
Detailed analysis of the Asthma and COPD market. 10 year sales forecast for all major drugs brands in these indications, taking into account new treatment trends, clinical trial data, patent expirations and key new product launches in the 7 major markets.
HIV Reshaping Treatment Paradigms
HIV Reshaping Treatment Paradigms
Detailed analysis of the antiretroviral therapy market. 10 year sales forecast for marketed drugs and key pipeline compounds, factoring in clinical trial results, new product launches and patent expiries.

 

Scope of this report

 

 

* In-depth analysis of the current HIV market across the major US and EU markets

 

* Thorough assessment of underlying commercial and clinical factors shaping the antiretroviral market

 

* Detailed sales forecasts for the three major antiretroviral classes, molecules and brands in each of the six major markets

 

* Case study analysis of the entry inhibitor class focusing on the competitive environment and critical success factors
Upper GI Disorders Generics will limit pipeline profit
Upper GI Disorders Generics will limit pipeline profit
Gastroesophageal reflux disease (GERD), functional dyspepsia (FD) and peptic ulcer disease (PUD) represent a group of common gastrointestinal (GI) conditions, which can be referred to collectively as upper GI disorders. Gastric acid suppression remains the cornerstone of therapy in upper GI disorders, with particular focus on reducing symptoms and eradicating H. pylori, if present.
Top 20 Cancer Therapy Brands Sales of targeted therapies overtake cytotoxics in 2006
Top 20 Cancer Therapy Brands Sales of targeted therapies overtake cytotoxics in 2006
Sales of the Top 20 cancer therapy brands in each of the seven major markets totaled $24.5 billion in 2006 and are forecast to grow at a CAGR of 6.6% to $45.9 billion by 2016. Four newly marketed drugs are expected to become part of the Top 20 cancer therapy brands during the forecast period and are set to increase the 2016 sales of the existing Top 20 cancer therapy brands to $52.7 billion.
Disease Management and Drug Adherence Strategies to support patients and enhance treatment persistence
Disease Management and Drug Adherence Strategies to support patients and enhance treatment persistence
Failure to take medication as prescribed significantly increases the risk that patients will experience complications resulting in injury or death, and propagate higher healthcare costs overall. The medical establishment's approach to adherence is changing as it becomes clear that the responsibility of achieving adherence is not solely the patient's, but rather is shared among stakeholders.
Primary Brain Cancer
Primary Brain Cancer
Incidence of primary brain cancer across the seven major markets in 2007 is estimated to be 47,000. Over half of these cases will be glioblastoma multiforme, for which survival prospects are dismal. The median survival for this group of patients is 1.2 years and only 27% of patients are alive after two years. The level of unmet need is therefore high in this disease.
Depression Atypical lifecycle management strategy rejuvenates depression market
Depression Atypical lifecycle management strategy rejuvenates depression market
Novel pipeline drugs, lifecycle management of the current branded antidepressants, and development of atypical antipsychotics for depression are set to grow the depression market through to 2010 when it will peak at $14.6 billion. Thereafter, however, generic incursion of the atypical antipsychotics and the remaining branded antidepressants will see the depression market value drop to 2016.
Insomnia Strong brand identity critical to differentiation in an increasingly crowded market
Insomnia Strong brand identity critical to differentiation in an increasingly crowded market
Ambien has remained the clear leader in the insomnia market for over a decade, with 2006 sales of over $2.3 billion across the seven major markets. The success of Ambien is attributable to a favorable side-effect profile and half-life. However, due to recent patent expiries in the US and Japan, Ambien's leadership status is finally under threat and the market is undergoing some dramatic changes.
Multiple Sclerosis Continued growth makes the MS market a highly attractive investment
Multiple Sclerosis Continued growth makes the MS market a highly attractive investment
The dynamic MS market continues to grow unabated; seven major market revenues increased 14.7% from 2005 to $4.6 billion in 2006. Growth is driven by the highly successful beta-interferon brands, Teva's Copaxone (glatiramer acetate), and the recent relaunch of Tysabri; the first launch of a new MS treatment for six years.
Osteoporosis Risk management and reformulation offer best defense against generic onslaught
Osteoporosis Risk management and reformulation offer best defense against generic onslaught
The osteoporosis market is due a major upheaval when market leader Fosamax (alendronate) loses its US patent. The resultant heightened competition will force market players to implement radical lifecycle management strategies to safeguard their franchise revenue. New market entrants provide further complexity to the competitive landscape but will also drive market growth over the next ten years.
Monoclonal Antibodies Report Part I
Monoclonal Antibodies Report Part I
The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2012 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.
Spending on Telehealth Solutions in Europe 2007 to 2012 (Databook)
Spending on Telehealth Solutions in Europe 2007 to 2012 (Databook)
The telehealth market will continue to grow as the population, particularly the elderly and chronically ill, and technology adoption increase.
Spending on Telehealth Solutions in North America through 2007 to 2012 (Databook)
Spending on Telehealth Solutions in North America through 2007 to 2012 (Databook)
The telehealth market will continue to grow as the population, particularly the elderly and chronically ill, and technology adoption increase.
Irritable Bowel Syndrome Potentially profitable market is open for the taking
Irritable Bowel Syndrome Potentially profitable market is open for the taking
Irritable bowel syndrome (IBS) is a common disease affecting 1020% of the total adult population, particularly women, in which recurrent abdominal pain or discomfort is associated with defecation or changes in bowel habit. The majority of sufferers have never consulted a physician about their symptoms and remain undiagnosed.
Supportive Care in Oncology Significant growth opportunities exist in new supportive care indications
Supportive Care in Oncology Significant growth opportunities exist in new supportive care indications
Supportive care can be defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies, in particular cytotoxic chemotherapy. While the antihormonal therapies and novel molecular targeted therapies do not exist without some toxicity, these are not as severe as those associated with chemotherapy.
Hepatocellular Carcinoma Opportune indication for novel therapies
Hepatocellular Carcinoma Opportune indication for novel therapies
The close association with hepatitis means that hepatocellular carcinoma (HCC) is common in developing countries where hepatitis B and C infections are endemic. However, the increasing prevalence of hepatitis in the West means that incidence of HCC in the US and Europe is expected to increase significantly over the coming years.
Generic Series An Introduction to the Canadian Generics Market Key trends and leading companies shaping the market
Generic Series An Introduction to the Canadian Generics Market Key trends and leading companies shaping the market
The Canadian pharmaceutical market is the 8th largest globally and as such represents an important market for generics manufacturers. Although historically dominated by domestic generics companies, mergers and acquisitions over the last five years have increased the dominance of foreign players.
Female Sexual Dysfunction Results from Datamonitor's 2005 physician survey
Female Sexual Dysfunction Results from Datamonitor's 2005 physician survey
Patients in a clinical population receive drug and non-drug therapy for female sexual dysfunction, yet a third remain refractory to treatment, highlighting a need for a formally approved product for FSD. There is a low level of satisfaction with the classification guidelines, further limiting diagnosis, already hampered by embarrassment, lack of physician awareness and an unclear referral system.
Fibromyalgia Potentially lucrative market soon to become reality
Fibromyalgia Potentially lucrative market soon to become reality
Mainly affecting women, fibromyalgia syndrome affects six million people in the US alone. This relatively common yet poorly understood syndrome is characterized by widespread muscle pain and fatigue and remains substantially underserved by the medical profession and the pharmaceutical industry. Currently, there are no drugs licensed to treat fibromyalgia in the US, Japan or Europe.
Disease Modification in Rheumatoid Arthritis Competition for the anti-TNF failure patient population increases
Disease Modification in Rheumatoid Arthritis Competition for the anti-TNF failure patient population increases
The treatment of Rheumatoid Arthritis (RA) has been rapidly evolving over the last decade. The success of the next wave of novel RA therapies depends on their ability to address the key issue of cost effectiveness, as the patient population for anti-TNF's is reaching a maximum and competition moves to anti-TNF failure patients.
Insomnia Targeting the sleep maintenance market
Insomnia Targeting the sleep maintenance market
The launch of serotonin antagonists which are largely aimed at treating sleep maintenance is set to make a substantial impact on the insomnia market, which will increase in value across the seven major markets from $6.1 billion in 2006 to $7.7 billion in 2016.
Benchmarking Patent Expiries Key Factors Affecting Brand Erosion at Patent Expiry
Benchmarking Patent Expiries Key Factors Affecting Brand Erosion at Patent Expiry
With declining returns from drug development pipelines, preservation of branded revenues is key for manufacturers. Inevitably though, once the core product patent of a pharmaceutical drug expires, generic companies will launch their own, cheaper versions of the drug, encouraging product switching and eroding the revenues of branded pharmaceuticals.
Antithrombotics Reaching the untreated prophylaxis market
Antithrombotics Reaching the untreated prophylaxis market
Novel oral anticoagulants and antiplatelet agents will have a profound impact on the antithrombotics market. Datamonitor expects Bayer's rivaroxaban and Sankyo/Eli Lilly's prasugrel to achieve blockbuster status. Parenteral anticoagulants are not expected to be large revenue generators, due to low clinical unmet need in this market segment and strong competition from current gold standard agents.
Dyslipidemia - Pipeline agents unlikely to rejuvenate the market
Dyslipidemia - Pipeline agents unlikely to rejuvenate the market
At present, despite the availability of numerous agents for the treatment of dyslipidemia, there is significant scope for expanding the market by improving diagnosis and treatment of dyslipidemia patients. However, for new agents, gaining a secure foothold on the market will be challenging, but their chances can be improved through targeting niche patient populations and conducting outcome trials.
Influenza Vaccines - Pandemic threat revitalizes the sector
Influenza Vaccines - Pandemic threat revitalizes the sector
The influenza vaccine market, sized at approximately $2.2 billion in 2006, yields many challenges. Demand is highly variable, and only large players are able to cope with the need for annual updates and the costly manufacturing process. However, driven by the increasing pandemic threat, the market is growing fast and is predicted to more than double in size by 2016.
Hematological Malignancies Pursuit for the next blockbuster intensifies
Hematological Malignancies Pursuit for the next blockbuster intensifies
Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity. Pipeline candidates classified as molecular targeted therapies, cytotoxic therapies and immunotherapeutic agents, may offer attractive therapeutic additions and Datamonitor's insight into their clinical and commercial potential is provided.
Multiple Sclerosis The oral revolution
Multiple Sclerosis The oral revolution
The launch of five novel orally administered disease-modifiers is set to revolutionize the multiple sclerosis (MS) market, which will more than double in value across the seven major markets from 2006 to reach $10.7 billion in 2016.
Pricing and Reimbursement Series Medicare Part D's progress so far
Pricing and Reimbursement Series Medicare Part D's progress so far
The roll-out of Part D in January 2006 represented a significant leap forward, since it provided coverage for outpatient drugs for Medicare patients for the first time. A high number of both patients and insurance providers are now involved in the program, as a result of strong patient enrollment.
Asthma Phenotypes A changing paradigm
Asthma Phenotypes A changing paradigm
An estimated 34 million people are diagnosed with asthma in the major markets. The disease can be broken down into various phenotypes, differentiated by severity, trigger, or predominant inflammatory type. These phenotypes may have important consequences for future approaches to treat asthma in a more targeted fashion, doing away with the one-size-fits-all approach.
Depression Novel drugs to grow third-line market
Depression Novel drugs to grow third-line market
Datamonitor believes that companies developing pipeline drugs for the depression market should concentrate resources on targeting third-line depression patients, a market with significant sales volume and few viable treatment options. GSK's gepirone ER is likely to be the first pipeline drug to enter the market and exploit this opportunity, with forecast sales of $615m in 2016.
Nosocomial Infections The need for new gram-negative drugs
Nosocomial Infections The need for new gram-negative drugs
In the US and Europe, an estimated 510% of patients are expected to develop an infection during their hospital stay. The four main types of infections that occur within the hospital setting are urinary tract infections, hospital acquired pneumonia, surgical site infections and blood-stream infections, accounting for approximately 35%, 15%, 14% and 10% respectively.
ePrescribing Infrastructure and Impact on the Healthcare Markets in the US and EU
ePrescribing Infrastructure and Impact on the Healthcare Markets in the US and EU
Technology has been used to either inform or expedite the prescribing process in most modern healthcare systems for over two decades. Recently, market forces - including greater regulatory intervention, increased investment from stakeholders and decreased resistance from end-users - have begun to converge to set the stage for widespread adoption of truly integrated ePrescribing solutions.
Atopic Dermatitis A high level of unmet need creates market opportunities
Atopic Dermatitis A high level of unmet need creates market opportunities
Atopic dermatitis is a skin disorder characterized by intense itch, dry skin and redness. Often considered a benign disease, it actually impacts very negatively on quality of life, sometimes more than psoriasis and diabetes. Through opinion leader interviews, Datamonitor has identified a high level of unmet need in atopic dermatitis treatment and believe that a number of market opportunities exist
Small Cell Lung Cancer and Malignant Mesothelioma Limited R&D activity provides opportunity for early-phase pipeline drugs
Small Cell Lung Cancer and Malignant Mesothelioma Limited R&D activity provides opportunity for early-phase pipeline drugs
SCLC accounts for one-fifth of all lung tumor types. More than 80,000 new cases are expected to be diagnosed in 2007 in the seven major markets, although it is set to decrease due to changing smoking habits. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe and Japan given the heavy use of asbestos in the 1970s and long latency period of the disease.
Esophageal Cancer Treatment paradigms need revolution not evolution
Esophageal Cancer Treatment paradigms need revolution not evolution
Globally, esophageal cancer is the ninth most common tumor type and seventh leading cause of cancer-related death, however, its incidence fluctuates widely depending on geographical area. While relatively uncommon in Western countries, 50% of patients still present with locally advanced unresectable or distant metastatic disease, where treatment is complicated and chances of a cure are reduced.
The Pharmaceutical Industry Key trends and strategic issues shaping the industry
The Pharmaceutical Industry Key trends and strategic issues shaping the industry
Datamonitor has identified the key trends and events that impacted the pharmaceutical market on a macro-environmental and corporate strategy level in 2006. These range from the continuation of long term trends such as the focus on cost containment to more recent impacts such as the effects of Medicare Part D and the increasing power of the Democratic part in the US.
eHealth for the Pharmaceutical Industry What companies need to know about trends in physicians and consumers use of the Internet
eHealth for the Pharmaceutical Industry What companies need to know about trends in physicians and consumers use of the Internet
An understanding of the present and future market trends surrounding eHealth is vital in order for the pharmaceutical industry to develop effective multi-channel marketing strategies. It is advisable for stakeholders to invest in targeted initiatives that meet the specific information needs and support the decision making processes of the large numbers of physician and consumer groups online.
HIV Change of guard
HIV Change of guard
The HIV market generated $7.4 billion of sales in 2005 and experienced a CAGR of 13.3% from 2001-2005, making it one of the fastest growing infectious diseases sub sectors. Despite the antiretroviral market's relative immaturity, many older flagship products such as Combivir are expected to lose patent protection before 2015.
Psoriasis Anti-TNF's lead another indication
Psoriasis Anti-TNF's lead another indication
There is no cure for psoriasis, which profoundly affects sufferers quality of life, physical and social functioning. There is a particular unmet need for effective long-term therapies for psoriasis. Prevalence is the highest of the autoimmune diseases at 16 million in 2006, but this is deceptive in terms of market size, as the treated and severe patient populations are comparatively small.
Osteoarthritis Market sees steady growth
Osteoarthritis Market sees steady growth
The 2004 withdrawal of Vioxx from the global market had a negative effect on the COX-2 class, with a 44% fall in Celebrex sales for osteoarthritis in 2005. However, as patients sought an alternative to the COX-2s, there was positive growth in traditional NSAIDs, non-narcotic analgesics, narcotic analgesics, corticosteroids and HA viscosupplements, leading to a 1.1% increase in total market value.
Atherosclerosis HDL ApoA-I Carotid MRI and 64-slice CT offer opportunities for future treatment
Atherosclerosis HDL ApoA-I Carotid MRI and 64-slice CT offer opportunities for future treatment
Atherosclerosis generally begins in childhood and manifests clinically in mid-to-late adulthood. While the mortality from atherosclerotic conditions has declined significantly, in developed countries cardiovascular disease accounts for nearly 50% of all deaths, and within the next 15-20 years, is projected to surpass infectious diseases to become the leading cause of death worldwide.
Multiple Sclerosis Disease-modifying efficacy and side effects guide treatment choice
Multiple Sclerosis Disease-modifying efficacy and side effects guide treatment choice
The disease-modifying drugs are considered by physicians to represent a significant advance for the management of MS. However, none is fully effective and there are problems with regards to side effects, dosing regimens and cost. Tysabri, a novel once-monthly drug is expected to be an improvement in terms of efficacy; however, there remains a concern over side effects and long-term safety.
Erectile Dysfunction Identifying product differentiation and patient segmentation strategies
Erectile Dysfunction Identifying product differentiation and patient segmentation strategies
The erectile dysfunction market grew 3.5% from 2005 to be worth $1.95 billion in 2005 and is almost entirely composed of sales from three brands: Viagra (sildenafil), Cialis (tadalafil) and Levitra (vardenafil). Despite the dominance of these products, several opportunities exist for a successful market entry.
Melanoma Lucrative commercial opportunities persist
Melanoma Lucrative commercial opportunities persist
Melanoma comprises just 5% of all skin cancers but it is the most deadly. In 2006, more than 100,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced patients remains below 20%.
Respiratory Syncytial Virus RSV A market yet to reach its full potential
Respiratory Syncytial Virus RSV A market yet to reach its full potential
RSV mostly causes upper respiratory tract infections (URTI), resulting in the common cold. However, in certain risk groups, RSV can cause more severe lower respiratory tract infections (LRTI) leading to bronchiolitis. These risk groups include elderly people, patients with underlying pulmonary or cardiac disease, premature infants, children under four years old and immunocompromised patients.
Taking CRM to the Next Level Web-assisted relationship and community-building for the pharmaceutical industry
Taking CRM to the Next Level Web-assisted relationship and community-building for the pharmaceutical industry
CRM is a business strategy by which a company seeks to maximize the value of its products by managing the customer relationship, with specific aims to boost customer retention and increase market share, while reducing the costs of sales, marketing and customer fulfillment. CRM is made necessary because of advances in Web-enabled technologies, which have changed the dynamics of sales and marketing.
The Pharmaceutical Company Outlook to 2011 Financial and Strategic Analysis of the Sales Outlook for Big Pharma Mid Pharma Japan Pharma and Biotech
The Pharmaceutical Company Outlook to 2011 Financial and Strategic Analysis of the Sales Outlook for Big Pharma Mid Pharma Japan Pharma and Biotech
Based on an analysis of 46 companies and 1,000+ products, Datamonitor forecasts that pharmaceutical industry ethical sales will increase at a modest 4.9% CAGR 200511. However, behind this industry average figure there are strategic segments of the market that offer double-digit growth rates through barriers against generic competition and the opportunity for aggressive indication broadening.
Biosimilars Benchmarking the key players With increasing regulatory clarity and high revenue potential interest in biosimilars increases
Biosimilars Benchmarking the key players With increasing regulatory clarity and high revenue potential interest in biosimilars increases
With increasing regulatory clarity and the expiries of key patents covering innovator biologics, the development of biosimilars for a range of recombinant protein classes is becoming increasingly attractive. Although many companies are targeting the market, 12 companies dominate. These include established generics companies, leading biosimilars developers, plus emerging biosimilar developers.
Obesity Lack of Reimbursement Limits Market Potential
Obesity Lack of Reimbursement Limits Market Potential
Datamonitor predicts a somewhat enthusiastic uptake of two agents currently in development by 2015. However, reimbursement is critical to the uptake of new medication, due to the high cost of therapy. If the reimbursable status is not achieved, the expansion of the market will not match the rate of growth of the obese population and the great potential of the obesity market will remain untapped.
Antibacterials Growth in resistance rates drives niche indications
Antibacterials Growth in resistance rates drives niche indications
The global antibacterial market, valued at $25.5 billion in 2005, is highly mature. Modest growth (CAGR 2001-2005: 5.1%) is fuelled by ageing, immunosuppression and emerging resistances, especially in the hospital and former niche markets (e.g. MRSA). The community market, however, is facing a value loss following the patent expiries of several blockbusters (e.g. Pfizer's Zithromax) in 2005.
Therapeutic Cancer Vaccines A turbulent path from bench to bedside
Therapeutic Cancer Vaccines A turbulent path from bench to bedside
Unmet needs across the cancer market remain high, with most therapies conferring low levels of specificity and high toxicity. Therapeutic cancer vaccines offer an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. However, despite years of R&D, a reproducible survival benefit has proved elusive, leaving the market wide open.
Alzheimer's Disease Prescribing trends indicate that neurologists are not adhering to guidelines
Alzheimer's Disease Prescribing trends indicate that neurologists are not adhering to guidelines
A lack of prescriber adherence to both marketing licenses and pharmacoeconomic guidelines represents both a challenge and opportunity for pharmaceutical companies marketing current Alzheimer's disease drugs. Indication expansion between disease severities may not be a viable commercial option; conversely, stricter guidelines by bodies such as the UK's NICE will not necessarily threaten the market.
Chinese Pharmaceutical Market Overview Regulatory reform and the evolving healthcare market provide opportunities in china
Chinese Pharmaceutical Market Overview Regulatory reform and the evolving healthcare market provide opportunities in china
The Chinese pharmaceutical market, although only positioned ninth globally, has experienced pronounced and rapid expansion in recent years, driven by the growth of both Chinese and Western manufacturers. Increasingly, there is a shift towards a research-based industry, focused on generating new, innovative therapies, supported by improving intellectual property regulations.
Antithrombotics Pipeline products to dampen the impact of patent expiries and cost containment initiatives
Antithrombotics Pipeline products to dampen the impact of patent expiries and cost containment initiatives
The ageing of the population will result in an increased incidence of coronary artery disease, heart failure and stroke. In addition to these epidemiological forces, the antithrombotics market will be sustained by the forthcoming launch of innovative novel agents whose sales revenue is expected to dampen the commercial impact of generic incursion in blockbuster proceeds.
Migraine Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries
Migraine Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries
After the launch of Trexima in 2007, triptan genericization coupled with a weak late-stage pipeline will result in a major shift in market dynamics, and will result in the migraine market value decreasing to $3.2 billion in 2015. The market remains receptive to superior prophylactics however, with innovation being essential for the progression of the acute market, post-triptan era.
Pricing and Reimbursement in Oncology Do payers believe oncology drugs offer good value
Pricing and Reimbursement in Oncology Do payers believe oncology drugs offer good value
The oncology market has shown remarkable growth in recent years, driven by the advent of targeted therapy and the high level of unmet needs in the disease, and it is poised for further expansion. While this will provide companies with opportunities, a key hurdle for novel cancer drugs will be the increasing pharmacoeconomic vigilance that prevails within cash-strapped healthcare systems.
Gynecological Cancers Niche opportunities in advanced disease
Gynecological Cancers Niche opportunities in advanced disease
Cases of endometrial cancer are set to rise in developed countries due to an increase in risk factors such as obesity. In contrast, while incidence of cervical cancer is set to decrease in developed countries following the implementation of anti-HPV immunization with Merck & Co's Gardasil and GlaxoSmithKline's Cervarix, it will remain a major cause of cancer-related death in the developing world.
Biosimilars Regulatory Issues Europe continues to make strides while the US lags behind
Biosimilars Regulatory Issues Europe continues to make strides while the US lags behind
The drive for increased cost savings by healthcare providers is increasing the focus on boosting the biosimilar market. With a regulatory approval pathway in place in Europe and substantial guidelines to support biosimilar development, the European biosimilars market is significantly more advanced than the US, where plans for a biosimilar regulatory approval pathway have stalled.
Drug Delivery Global Industry Guide
Drug Delivery Global Industry Guide
Datamonitor's Drug Delivery: Global Industry Guide is an essential resource for top-level data and analysis covering the drug delivery industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Biotechnology Global Industry Guide
Biotechnology Global Industry Guide
Datamonitor's Biotechnology: Global Industry Guide is an essential resource for top-level data and analysis covering the biotechnology industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Next-Generation Nutraceuticals Food and pharma convergence in disease prevention and personalized nutrition
Next-Generation Nutraceuticals Food and pharma convergence in disease prevention and personalized nutrition
Today, consumers are taking a more proactive approach to managing their health and the prevention of diet-related diseases, such as obesity, diabetes, cardiovascular and bone and joint diseases. Many of these diseases are at epidemic levels, and this combined with increasing patient power makes the prevention of these lifestyle diseases attractive markets for both the food and pharmaceutical industries to exploit.
Generics Global Industry Guide
Generics Global Industry Guide
Datamonitor's Generics: Global Industry Guide is an essential resource for top-level data and analysi